KR20150049667A - Composition for improving atopic skin comprising 7, 8, 4'-trihydroxyisoflavone as active ingredient - Google Patents

Abstract

The present invention relates to a composition for preventing or treating atopic dermatitis and, more specifically, to a pharmaceutical composition for preventing or treating atopic dermatitis or a cosmetic composition for alleviating atopic dermatitis, wherein 7, 8, 4′-trihydroxyisoflavone is contained as an active ingredient.

Description

 The present invention relates to a composition for improving atopic dermatitis comprising 7, 8, 4'-trihydroxyisoflavone as active ingredient,

The present invention relates to a composition for preventing or treating atopic dermatitis, and more particularly, to a pharmaceutical composition for preventing or treating atopic dermatitis comprising 7, 8, 4'-trihydroxyisoflavone as an active ingredient and a cosmetic composition for improvement .

In general, atopy means 'abnormal reaction', 'strange', 'meaning can not be understood' as the etymology of Greek, as it is etymologically, various causes of atopic dermatitis are complicatedly intertwined, , Is a skin disease that is difficult to treat.

Atopy refers to a series of allergic symptoms that appear in the skin, respiratory mucosa, mucous membranes, mucus membranes, and the immune membranes in an individual with atopic asthma. Such atopic asthma (allergic constitution) is inherited and appears as a family, and allergic diseases caused by atopic asthma , Allergic rhinitis, asthma, allergic conjunctivitis, atopic allergies, etc. These diseases may occur singly or in several diseases at the same time.

The major symptom of atopic dermatitis is chronic dryness, severe fever, recurrent recurrence, subacute lesions of erythematous rash with exudation, chronic lesions thickening like skin, leading to hematoma, edema and destruction of skin barrier .

In atopic dermatitis patients, cytokine released from T cells has been reported to be the main cause of dermatitis. In particular, T helper cells (CD4 + T cells) decrease the ratio of inhibitory T cells and Th2 cells are divided into Th1 and Th2 cells. If the balance is lost, the immune response may be abnormal have.

IL-4 produced by Th2 predominantly acts in the state of atopic dermatitis. In other words, IL-4 receptor promotes differentiation and growth into Th2 cells by exposure to IL-4, leading to the reaction of Th2 cells. IL-4 inhibits the differentiation into Th1 cells and stimulates B cells to promote IgE production do. IFN-y produced by Th1 cells is involved in chronic atopic dermatitis unlike the action in Th2 cells. In contrast to the action of IL-4, the rise of IFN-γ is known to inhibit the production of IgE and the expression of IL-4 receptor in T cells.

In addition, when atopic dermatitis progresses, mast cells are observed in the skin lesion, mast cells are activated by IgE receptor, releasing histamine and TNF-α, IL-4 and IL-6 related to inflammation in the degranulation process, Keep inflammatory cells in your skin.

Steroids are known to be the most effective drugs currently used. However, when they are used as anti-inflammatory drugs for a short period of time, they show excellent effects. However, when used for a long period of time, they have a problem of recurrence due to increased skin resistance and skin tolerance to atopic dermatitis.

Therefore, development of a material capable of improving atopic dermatitis without progression of such side effects is actively under way.

For example, Korean Patent Registration No. 431076 discloses a cosmetic composition for improving healing of atopic skin including white wool, barley, Echinacea and fermented soybean extract, Korean Patent Laid-Open Publication No. 2004-0065126 discloses a natural ganoderma mushroom, Herbal botanical composition having an effect on healing and prevention of atopic skin including herbal botanical extracts obtained from licorice, white bream, white jasmine, and white herb.

Korean Patent No. 431076 Korean Patent Publication No. 2004-0065126

Accordingly, the present inventors have made efforts to find a composition effective for improving atopic dermatitis. As a result, the present inventors have found that 7,8, 4'-trihydroxyisoflavone is effective in alleviating atopic dermatitis and is effective in atopic dermatitis, The present invention has been accomplished by confirming that it reduces edema, serum IgE and mast cell count, Th2-related cytokine, and reduces the epidermal water loss (TEWL).

Accordingly, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating atopic dermatitis comprising 7,8, 4'-trihydroxyisoflavone as an active ingredient.

It is another object of the present invention to provide a cosmetic composition for improving atopic dermatitis comprising 7, 8, 4'-trihydroxyisoflavone.

To this end,

There is provided a pharmaceutical composition for treating or preventing atopic dermatitis comprising 7,8, 4'-trihydroxyisoflavone represented by the following formula (1) as an active ingredient:

The present invention also provides a cosmetic composition for improving atopic dermatitis containing 7,8, 4'-trihydroxyisoflavone represented by the above formula (1) as an active ingredient.

The 7, 8, 4'-trihydroxyisoflavone of the present invention markedly improved the symptoms of atopic dermatitis in atopic animal model NC / Nga mice that caused atopic dermatitis, decreased serum IgE antibody concentration, -4, IL-5, and IL-13, respectively. It also reduces transepidermal water loss (TEWL) through the epidermis. Accordingly, the pharmaceutical composition of the present invention containing the compound of Formula 1 can be usefully used for the prevention or treatment of atopic dermatitis. In addition, the cosmetic composition of the present invention containing the compound of formula (1) can be useful as a cosmetic for improving atopic dermatitis, that is, as an anti-atopic functional cosmetic.

FIG. 1 is a photograph of mouse skin appearance after 7, 8, 4'-trihydroxyisoflavone was applied to an NC / Nga mouse model of an atopic dermatitis animal for 3 weeks.
FIG. 2 shows the results of measuring the dermatitis index of each group of mice after applying 7, 8, 4'-trihydroxyisoflavone to NC / Nga mouse, an animal model of atopic dermatitis for 3 weeks.
Figure 3 shows the results of measuring changes in ear thickness for each group of mice after applying 7, 8, 4'-trihydroxyisoflavone to NC / Nga mice, an animal model of atopic dermatitis for 3 weeks .
FIG. 4 shows the result of measuring the change in serum IgE concentration in each group of mice after applying 7, 8, 4'-trihydroxyisoflavone to NC / Nga mouse, an animal model of atopic dermatitis for 3 weeks .
FIG. 5 is a graph showing the effect of 7, 8, 4'-trihydroxyisoflavone on NC / Nga mouse model of atopic dermatitis for 3 weeks. Eosinophil staining photographs and cell The results of measurement of number change are shown.
FIG. 6 is a graph showing the effect of 7, 8, 4'-trihydroxyisoflavone on NC / Nga mice, an animal model of atopic dermatitis, for 3 weeks. Mice of each group were stained for mast cells, The results of measurement of number change are shown.
FIG. 7 is a graph showing inhibition of the production of MDC and TARC when 7, 8, 4'-trihydroxyisoflavone was treated with INF-γ-stimulated HaCaT cells.
Figure 8 shows that 7, 8, 4 ' -trihydroxyisoflavones were applied to NC / Nga mice, an animal model of atopic dermatitis, for 3 weeks, and serum levels of Th2 cytokines IL- 5 < / RTI > and < RTI ID = 0.0 > IL-13. ≪ / RTI >
FIG. 9 is a graph showing trans epidermal water loss for 7,8, 4'-trihydroxyisoflavone. FIG.

Hereinafter, the present invention will be described in detail.

The 7,8, 4'-trihydroxyisoflavone contained as an active ingredient in the composition according to the present invention has a structure represented by the following formula (1).

[Chemical Formula 1]

The compound of formula (1) Atopic dermatitis induced atopic dermatitis Model NC / Nga mice significantly improved the symptoms of atopic dermatitis and decreased serum IgE antibody levels as well as IL-4, IL-5 and IL-13 Th2-related cytokines The amount was reduced. It also reduces transepidermal water loss (TEWL) through the epidermis.

Accordingly, the composition comprising the compound of Formula 1 as an active ingredient may be formulated into a pharmaceutical composition for treating or preventing atopic dermatitis or a cosmetic composition for improving atopic dermatitis.

When formulated into a pharmaceutical composition, the composition of the present invention can be formulated by a method known in the pharmaceutical field and mixed with a pharmaceutically acceptable carrier, excipient or the like to prepare a conventional pharmaceutical preparation, for example, a liquid preparation, Capsules, granules, powders, ointments, emulsions, gels, creams, and the like, and they can be administered by various routes. It may be formulated into a transdermal dosage form such as a solution, gel, emulsion, suspension, microemulsion, microcapsule, liposome, cream, lotion, ointment, aerosol, spray, paste and patch.

The pharmaceutical composition of the present invention contains 0.001 to 10% by weight of 7,8, 4'-trihydroxyisoflavone of the above formula (1) in the whole pharmaceutical composition. The pharmaceutical composition thus prepared is used at an effective dose of 0.00001 mg / kg to 400 mg / kg per dose, and the actual dose of the active ingredient is determined according to the severity of symptoms, the route of administration selected, the age, sex, Should be determined in light of the various relevant factors of the disease. Accordingly, the above dose is not intended to limit the scope of the present invention in any way. The administration can be administered once to several times a day.

When formulated into a cosmetic composition, the content of 7,8, 4'-trihydroxyisoflavone of Formula 1 is 0.0001 to 10% by weight, preferably 0.01 to 5.0% by weight based on the total weight of the cosmetic composition. The content of 7,8, 4'-trihydroxyisoflavone is preferably at least the above-mentioned minimum value so as to achieve a minimal effect of improving atopic dermatitis. , And the content of 8,4'-trihydroxyisoflavone is preferably below the maximum value. At this time, it is preferable that the content of 7,8, 4'-trihydroxyisoflavone is appropriately adjusted within the above range according to the content of the components contained in the formulation or cosmetic composition.

The ingredients contained in the cosmetic composition of the present invention include components commonly used in cosmetic compositions in addition to the 7,8, 4'-trihydroxyisoflavone as an active ingredient, such as antioxidants, stabilizers, solubilizers, vitamins, Customary adjuvants such as pigments and flavors, and carriers.

The composition of the present invention can be prepared in any formulations conventionally produced in the art, and can be used in various forms such as softening agents, convergent lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, eye essence, A cleansing foam, a cleansing water, a pack, a gel, a powder, a body lotion, a body cream, a body oil, a body essence and the like.

When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.

Hereinafter, preferred embodiments of the present invention will be described. The following examples are provided for the purpose of more clearly illustrating the present invention and the present invention is not limited to the following examples.

Experimental Example 1: Effect of atopic dermatitis symptom on NC / Nga mouse

In order to confirm the efficacy of the 7,8,4'-trihydroxyisoflavone of the present invention for improving atopic dermatitis, an atopic dermatitis animal model NC / Nga mouse was injected with dinitrocobenzene (DNCB), an atopy inducing agent, And atopic dermatitis, the skin condition and dermatitis score were scored to identify clinical symptoms. At this time, dinitrochlorobenzene was dissolved in a solvent (acetone: olive oil = 3: 1 mixture) so as to have a concentration of 0.2%.

All animals were given free diet and drinking water. A total of 45 experimental animals were used, and each group was divided into 5 groups and 9 animals were assigned to each group. Ninety liters of ethanol (190 μl) were administered without DNCB, 9 mice were administered with DNCB and 190 μl of ethanol were administered orally. At the time of application of DNCB, 7, 8, 4'-trihydroxyisobutyrate (N = 9), tacrolimus (dose: 100 ㎍), and tacrolimus-treated tacrolimus group (n = 9) were administered in combination with skin application (200 nmol, ethanol) Respectively.

8 weeks old female NC / Nga mice were cleaned and then allowed to stand for 24 hours to heal the skin micro-wounds that may occur during the hair removal process. Twenty-four hours later, 190 μl of 1% DNCB per mouse was applied to the back of the back and both ears to induce atopic dermatitis. After 4 days, 190 [mu] l of 0.2% DNCB was evenly applied to the same site for three weeks a week to maintain atopic dermatitis. Samples were applied daily from the beginning of the experiment. The dermatitis index was calculated by evaluating gross changes of erythema, hemorrhage, and scar from 0 to 3 points by observing the lesion once a week.

As a result of the experiment, it was confirmed that 7,8,4'-trihydroxyisoflavone improves atopic dermatitis induced state to some extent (FIG. 1).

FIG. 2 shows the results of measuring the dermatitis index of each group of mice after applying 7, 8, 4'-trihydroxyisoflavone to NC / Nga mouse, an animal model of atopic dermatitis for 3 weeks.

Referring to FIG. 2, the 7,8,4'-trihydroxyisoflavone of the present invention improves the dermatitis index, and it is confirmed that the atopic dermatitis induced condition similar to that of tacrolimus used as a treatment for atopic dermatitis is improved.

Experimental Example 2: Effect on ear edema in NC / Nga mice

At the beginning of the experiment, changes in ear thickness were measured while observing the external changes (erythema, itching, dry skin, edema, erythema and firing) of the skin tissue of mice and the like. Ear swelling was performed with vernier calipers (Mitutoyo, Japan).

After autopsy, mouse ear tissues were extracted and stained with hematoxylin-eosin (H & E) method, and the skin thickness was observed with an optical microscope. The gluma of the mouse was measured once a week for 3 weeks. The results are shown in Fig.

Figure 3 shows the results of measuring changes in ear thickness for each group of mice after applying 7, 8, 4'-trihydroxyisoflavone to NC / Nga mice, an animal model of atopic dermatitis for 3 weeks .

As shown in FIG. 3, it was confirmed that the thickness of the ear thickened by DNCB was decreased by application of 7, 8, 4'-trihydroxyisoflavone, and it was confirmed that the condition of atopic dermatitis was improved similarly to tacrolimus Respectively.

Experimental Example 3: Effect on serum IgE concentration in NC / Nga mouse, an atopic experiment animal

At the end of the experiment, the blood was drawn from the heart into syringes and centrifuged at 3,000 rpm at 4 ° C for 10 minutes to separate the serum. They were kept in a -75 ° C freezer until used in the experiment. The IgE concentration in serum of NC / Nga mice was measured using an ELISA (enzyme-linked immunosorbent assay kit (Shibayagi)). To each 96-well plate, 0.2 μl of the serum from the mouse and 199.8 μl of a dilution buffer were mixed, and 50 μl of the diluted buffer was added to each well. The mixture was placed on a shaker at room temperature for 2 hours And then washed three times with washing buffer solution for 5 minutes each.

The biotin-conjugated anti-IgE antibody was added again, and the mixture was allowed to stand at room temperature for 2 hours and then washed three times. HRP-conjugated avidin (50 μl) was added, placed on a shaker at room temperature, allowed to stand for 1 hour, and then washed again. 50 Ch of Chromogenic substrate reagent (TMB) was added and incubated for 5 minutes. Then, 50 의 of stop solution was added and absorbance was measured in an ELISA reader (450 nm). The results are shown in Fig.

Referring to FIG. 4, the concentration of serum IgE increased in the DNCB-treated group was decreased in the 7, 8, 4'-trihydroxyisoflavone application group.

Experimental Example 4: Effect on suppression of immune tissue infiltration in NC / Nga mouse, an atopic experimental animal

Three weeks after the induction of atopic dermatitis, mice were sacrificed and the dorsal skin was harvested, stained with toluidine blue to identify mast cells, and cultured in Congo red (R) to identify eosinophilic leukocytes (Congo red), and the number of mast cells or eosinophil cells present in the skin between the muscle tissues from the epidermis was counted by observing at 400x magnification under an optical microscope. The results are shown in Fig. 5 and Fig.

5, when the infiltration of lymphocytes and mononuclear cells was observed, a number of immune cells were stained purple in the control group. However, in the 7, 8, 4'-trihydroxyisoflavone application group, a very small number of immune cells Respectively. To confirm the infiltration of mast cells in inflammatory tissues, toluidine blue

blue) staining showed that the number of mast cells was increased in the atopic dermatitis-induced control group compared with the non-induced group, but the number of mast cells decreased in the 7, 8, 4'-trihydroxyisoflavone application group as compared with the control group. In the actual dyed photographs, a large number of mast cells were observed in the atopic dermatitis-induced control group while a small number of cells were observed in the 7, 8, 4'-trihydroxyisoflavone application group.

Experimental Example  5: MDC  And TARC  Production inhibition activity experiment

Three weeks after inducing atopic dermatitis, the mice were sacrificed and the dorsal skin was harvested and stored in a -75 ° C freezer until used in the experiment.

For the cytokine measurement, the skin of the mice and the like was cut into small pieces and 400 μl of RIPA lysis buffer was added thereto, followed by homogenization until proteins were sufficiently dissolved. The obtained protein was measured using an enzyme-linked immunosorbent assay (ELISA) kit (R & D Systems, Minneapolis, MN, USA).

On the day before the experiment, the capture antibody is dispensed into 96-well plates and overnight at room temperature. After washing three times for 5 minutes with washing buffer solution, 50 μl of the protein taken from the mouse was dispensed into each well and allowed to stand at room temperature for 2 hours and then washed three times.

The biotin-conjugated anti-IgE antibody was added again, and the mixture was allowed to stand at room temperature for 2 hours and then washed three times. HRP-conjugated avidin (50 μl) was added and allowed to stand at room temperature for 20 minutes and then washed again. Substrate reagent A and B were mixed at a ratio of 1: 1, and 50 μl of the mixture was allowed to stand for 20 minutes. Then, 25 μl of stop solution was added thereto and absorbance was measured in an ELISA reader (450 nm). The cytokine level obtained by measuring the absorbance was divided by the Lowry protein quantification value, and the experimental result was deduced.

MDC and TARC production inhibitory activity test results are shown in Fig.

As a result of FIG. 7, Tachymuth increased MDC, but 7, 8, 4'-trihydroxyisoflavone showed MDC and TARC production inhibitory activity.

Experimental Example  6: Th2  Related cytokine production inhibitory effect

Three weeks after inducing atopic dermatitis, the mice were sacrificed and the dorsal skin was harvested and stored in a -75 ° C freezer until used in the experiment.

For the cytokine measurement, the skin of the mice and the like was cut into small pieces and 400 μl of RIPA lysis buffer was added thereto, followed by homogenization until proteins were sufficiently dissolved. The obtained protein was measured using an enzyme-linked immunosorbent assay (ELISA) kit (R & D Systems, Minneapolis, MN, USA).

On the day before the experiment, the capture antibody is dispensed into 96-well plates and overnight at room temperature. After washing three times for 5 minutes with washing buffer solution, 50 μl of the protein taken from the mouse was dispensed into each well and allowed to stand at room temperature for 2 hours and then washed three times.

The biotin-conjugated anti-IgE antibody was added again, and the mixture was allowed to stand at room temperature for 2 hours and then washed three times. HRP-conjugated avidin (50 μl) was added and allowed to stand at room temperature for 20 minutes and then washed again. Substrate reagent A and B were mixed at a ratio of 1: 1, and 50 μl of the mixture was allowed to stand for 20 minutes. Then, 25 μl of stop solution was added thereto and absorbance was measured in an ELISA reader (450 nm). The cytokine level obtained by measuring the absorbance was divided by the Lowry protein quantification value, and the experimental result was deduced. The results are shown in Fig.

Referring to FIG. 8, the Th2 cytokines IL-4, IL-5 and IL-13 were decreased in the group treated with 7, 8, 4'-trihydroxyisoflavone. These results demonstrate that 7,8, 4'-trihydroxyisoflavone is effective in inhibiting atopic dermatitis lesions and inhibiting the immune response associated therewith.

Experimental Example  7: Percutaneous water loss  Measure

(Tewameter TM300, C + K electronic GmbH, Germany) was placed in contact with the surface of the back skin and lightly pressed to record the values. The transdermal water loss (TEWL) was found to be higher as the atopic symptoms were more severe, and the results are shown in FIG.

As shown in FIG. 9, the amount of light skin loss in each group was the highest in the atopic dermatitis group, the atopic dermatitis group, and the lowest in the normal group, and the concentration of 7,8, 4'-trihydroxy It was confirmed that isoflavone suppressed the moisture loss of the epidermis.

Hereinafter, the formulation of the present invention is not limited to the formulations of the present invention, although external ointments for skin, flexible lotion, convergent lotion, nutritional lotion, nutritional cream, massage cream, essence and pack are exemplified.

Formulation Example  1: Ointment for external skin

Skin external ointment was prepared according to a conventional method as shown in Table 1 below.

ingredient Content (% by weight) 7, 8, 4'-trihydroxyisoflavone 10 Diethyl sebacate 8 Nonsense 5 Polyoxyethylene oleyl ether phosphate 6 Sodium benzoate Suitable amount vaseline Balance Sum 100

Formulation Example  2: Softening longevity ( skin )

The number of softening times was determined according to a conventional method as shown in Table 2 below.

ingredient Content (% by weight) 7, 8, 4'-trihydroxyisoflavone One glycerin 5 1,3-butylene glycol 3 Betaine One Allantoin 0.1 DL-Panthenol 0.3 EDTA-2Na 0.02 Sodium hyaruronate powder 0.05 ethanol 5 Octyldodec-16 0.2 Polyoxyethylene hardened castor oil 0.2 incense Suitable amount antiseptic Suitable amount Pigment Suitable amount Purified water Balance Sum 100

Formulation Example  3: Nourishing lotion (lotion)

Nutritional lotion was prepared according to a conventional method as shown in Table 3 below.

ingredient Content (% by weight) Retinoid derivative 3 Glyceryl stearate SE 1.5 Cetearyl alcohol 1.0 Sheer butter 1.5 Polysorbate 60 1.3 Sorbitan stearate 0.5 Hardened vegetable oil One Mineral oil 5 Squalane 3 Cyclomethicone 2 Dimethicone 0.8 Tocopheryl acetate 0.5 Carbomer 0.12 glycerin 5 1,3-butylene glycol 3 Sodium hyaruronate powder 0.05 Triethanolamine 0.12 incense Suitable amount antiseptic Suitable amount Pigment Suitable amount Distilled water Balance Sum 100

Formulation Example  4: Nourishing cream

Nutritive creams were prepared according to the conventional method as shown in Table 4 below.

ingredient Content (% by weight) 7, 8, 4'-trihydroxyisoflavone 3 Pro-type glycerin monostearate 2 Cetearyl alcohol 2 Stearic acid 1.5 Polysorbate 60 1.5 Sorbitan stearate 0.6 Hydrogenated polyisobutene One Squalane 3 Mineral oil 5 Cyclomethicone 5 Dimethicone One Tocopheryl acetate 0.5 glycerin 5 Betaine 3 Triethanolamine One Xanthan gum 0.05 incense Suitable amount antiseptic Suitable amount Pigment Suitable amount Distilled water Balance Sum 100

Formulation Example  5: Massage  cream

A massage cream was prepared according to a conventional method as shown in Table 5 below.

ingredient Content (% by weight) 7, 8, 4'-trihydroxyisoflavone 3 Pro-type glycerin monostearate 1.5 Cetearyl alcohol 1.5 Stearic acid One Polysorbate 60 1.5 Sorbitan stearate 0.6 Isostearyl isoserate 5 Squalane 5 Mineral oil 35 Dimethicone 0.5 Hydroxyethylcellulose 0.12 glycerin 6 1,3-butylene glycol 3 Triethanolamine 0.3 incense Suitable amount antiseptic Suitable amount Pigment Suitable amount Distilled water Balance Sum 100

Formulation Example  6: Essence

The essence was prepared according to a conventional method as shown in Table 6 below.

ingredient Content (% by weight) 7, 8, 4'-trihydroxyisoflavone 3 glycerin 6 Betaine 5 PEG 1500 2 Allantoin 0.1 DL-Panthenol 0.3 EDTA-2Na 0.02 Hydrogenated lecithin 0.6 Hydroxyethylcellulose 0.1 Sodium hyaruronate powder 0.08 Carboxyvinyl polymer 0.2 Triethanolamine 0.2 Ceramide 0.2 Octyldodecanol 3 Squalane 3 Polysorbate 60 0.4 Glyceryl stearate SE 1.5 incense Suitable amount antiseptic Suitable amount Pigment Suitable amount Distilled water Balance Sum 100

Formulation Example  7: Pack

Packs were prepared according to a conventional method as shown in Table 7 below.

ingredient Content (% by weight) 7, 8, 4'-trihydroxyisoflavone One Polyvinyl alcohol 15 Cellulose sword 0.15 glycerin 3 PEG 1500 2 Betaine 2 DL-Panthenol 0.4 Allantoin 0.1 Triethanolamine 0.2 Nicotinamide 0.5 ethanol 6 PEG 40 hardened castor oil 0.3 incense Suitable amount antiseptic Suitable amount Pigment Suitable amount Distilled water Balance Sum 100

Claims (7)

A pharmaceutical composition for treating or preventing atopic dermatitis comprising 7,8, 4'-trihydroxyisoflavone represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]

The method according to claim 1,
Wherein the content of the 7,8, 4'-trihydroxyisoflavone is from 0.001 to 10% by weight based on the total weight of the total pharmaceutical composition. The method according to claim 1,
Wherein the composition has a formulation for dermal administration. 4. The composition according to claim 3, wherein the formulation for skin administration is selected from the group consisting of solutions, gels, emulsions, suspensions, microemulsions, microcapsules, liposomes, creams, lotions, ointments, aerosols, ≪ / RTI > A cosmetic composition for improving atopic dermatitis comprising 7,8, 4'-trihydroxyisoflavone represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]

6. The method of claim 5,
Wherein the content of the 7,8, 4'-trihydroxyisoflavone is from 0.001 to 10% by weight based on the total weight of the total cosmetic composition. 6. The method of claim 5,
The cosmetic composition of the present invention can be used for cosmetics such as softening lotion, convergent lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, gel, powder, body lotion, , And body essence. ≪ RTI ID = 0.0 > 11. < / RTI >

Images